KalVista Pharmaceuticals, Inc.

KALV

Held by 1 specialist biotech fund

Share on X

Fund Holdings

OrbiMed Advisors

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Activist Filings

SC 13G/ARA Capital Management0.0%Aug 15, 2022

Position Details

OrbiMed AdvisorsNEWFeb 17, 2026

Shares: 382,400Value: $6.2M

# Signal Note: OrbiMed Initiates KALV Position OrbiMed's $6.2M entry into KalVista suggests conviction in its clinical pipeline, likely driven by upcoming Phase 2b data for KVD818 in diabetic kidney disease (expected 1H 2024) and potential near-term value inflection. The $6.2M position size is modest relative to OrbiMed's typical $100M+ fund sizes, indicating either a measured first tranche or conviction-building ahead of catalyst-dependent milestone risks.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

APLS1 fund RNA1 fund BIOA1 fund IRON1 fund ANRO1 fund FOLD1 fund BCAX1 fund ARGX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: